Eli Lilly and Company

Kyowa Hakko Kogyo Co., Ltd.

Ligand Pharmaceuticals, Inc.

Douglas Linn Gernert

Timothy A Grese

Nathan Bryan Mantlo

Daniel Ray Mayhugh

Steven James Green

Kevin Matthew Gardinier

Christian Alexander Clarke

Marcus F Boehm

Yutaka Kanda

Paul Leslie Ornstein

Jon Kevin Reel

Shiro Akinaga

Warren Jaye Porter

Christopher Cioffi

Brian Morgan Watson

Robert Jason Herr

Pierre-Yves Michellys

David Andrew Neel

Tianwei Ma

Patrick Gianpietro Spinazze

Thomas John Bleisch

Richard Duane Johnston

Sean Patrick Hollinshead

Ana Maria Escribano

Freddie Craig Stevens

Jeffrey Michael Schkeryantz

Mitsunobu Hara

Patric James Hahn

Lance Allen Pfeifer

Albert Khilevich

Xiaodong Wang

Shinji Nara

Ana Isabel Mateo Herranz

William Glen Holloway

Maria Carmen Fernandez

Ashraf Saeed

Eva Maria Martin De La Nava

Todd Fields

Guoqing Cao

Rieko Nakatsu

Christopher M Mapes

Jun Eishima

Antonio Navarro

Cheryl Ann Carson

David Gene Barrett

Lacie Marie Chauvigne-hines

Jeffrey Michael Witkin

Michael John Rodriguez

Chong Si

Mohammed Sadegh Zia-Ebrahimi

Curren Tapfuma Mbofana

Spencer Brian Jones

Jason Eric Lamar

Almudena Rubio

Gaiying Zhao

The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.

AHR agonists

A TARP &#x3b3;8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N;A is andRis as defined herein;its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

[object Object]

Compounds of formula I wherein n, m, p, q, y, RR, R, R, R, and Rare as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

Compounds and methods for treating dislipidemia

The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C-Calkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.

Triazole PPAR modulators

The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

Retinoid X receptor modulators

This invention relates to substituted piperidine derivatives having at least one six-membered ring substituent. The piperidine derivatives exhibit antitumor activity and are useful as pharmaceuticals such as an antitumor agent.

Piperidine derivatives

Growing community of inventors

Indianapolis, IN, United States of America

Douglas Linn Gernert